European Radiotherapy Devices Market Research Report

The European radiotherapy market, mainly driven by the rapidly changing cancer treatment technology and the growing number of cancer patients, was valued at $915.4 million in 2013 and is expected to reach $1,028.1 million by 2018, at a CAGR of 2.3%.

The report analyzes the market of devices in terms of 3 segments, such as external beam radiation therapy, internal beam radiation therapy, and systemic radiation therapy. All of these segments are expected to experience a positive growth till 2018, owing to an increase in the cancer patient pool, and the increased awareness for procedures and sophisticated diagnostic techniques. The external beam radiotherapy market is the largest segment of the radiotherapy device market. With a market value of $1,427.1 million and $241.7 million, the external beam radiotherapy and internal beam radiotherapy segments have been contributing 76.0% and 12.9% to the total radiotherapy devices market. The markets have been witnessing significantly high growth because of the increase in the cancer patient pool.

In 2008, 2.5 million people were diagnosed with cancer in the European Union (EU27). Cancer is also the second most common cause of death in the region. 29% of deaths for men or 3 out of 10 deaths, 23% for women or 2 out of 10 deaths –figures that are expected to rise due to the ageing European population. The most frequently occurring forms of the disease in the EU are colorectal, breast, prostate and lung cancers. In men, lung cancer is the most frequent cause of cancer death, while in women, it is breast cancer. In both men and women, colorectal cancer is the second most common cause of cancer death.

The prevalence of cancer worldwide is around 7.4 million (53%) in males and 6.7 million (47%) in females, giving a male: female ratio of 10:9. In 2012, there were an estimated 14.1 million new cases of cancer diagnosed, in the world. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the U.S. Cancer remains the second most common cause of death in the U.S., accounting for nearly 1 of every 4 deaths.

The report also provides an extensive competitive landscaping of the leading companies operating in this market. The main companies extensively covered in this report are Varian Medical Systems, Elekta AB, Accuray Incorporation, Siemens, IBA S.A, and Covidien. Furthermore, the segment and country-specific company shares, news & deals, M&A, segment specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.

Customization Options:

Along with the market data, customize the MMM assessments to meet your company’s specific needs. Customize to get a comprehensive summary of the industry standards and a deep dive analysis of the following parameters:

Product Analysis:

Usage pattern (in-depth trend analysis) of products (segment-wise)

Product matrix, which gives a detailed comparison of product portfolio of each company, mapped at country and sub-segment levels

A comprehensive study of customers’ perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs

An analysis of overall brand usage and familiarity and brand advocacy distribution (Detractor/Neutral/Familiar)

Pricing Trends:

Cost Analysis of radiotherapy devices in the various countries in the region

Prostate cancer, brain cancer, lung, and head & neck cancers procedural investments in major countries of the region

Competitive Intelligence:

The company share analysis of the top players of the market in the region

The crucial developments and strategies that companies inculcate in their portfolio

Alternative Products: Impact analysis

MMM’s Healthcare Decision Making Quadrant: It is an innovative and useful quadrant for vendors who wish to analyze the potential growth markets based on parameters such as patient dynamics (patient pool, epidemiology of disease, preference towards surgeries/alternative therapies) and macroeconomic indicators (number of hospitals and cancer centers, reimbursement scenario, diagnosis rate, treatment rate and healthcare expenditure)

We will customize the research for you, in case the report listed above does not
meet with your exact requirements. Our custom research will comprehensively cover
the business information you require to help you arrive at strategic and profitable
business decisions.